• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva Pharmaceuticals

Teva wins FDA nod for migraine prevention drug

September 17, 2018 By Sarah Faulkner

Teva Pharmaceutical's Ajovy migraine drug

Teva (NYSE:TEVA) last week won FDA approval for its humanized monoclonal antibody, Ajovy, designed to prevent migraines. The treatment, which blocks the receptor for a protein that is linked to migraine pain, is available in quarterly and monthly-injection options. Amgen‘s (NSDQ:AMGN) competitive once-monthly product won FDA approval earlier this year. Teva studied Ajovy in two Phase […]

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Teva Pharmaceuticals

Teva wins FDA nod for sublingual film to treat opioid dependence

September 10, 2018 By Sarah Faulkner

Teva Pharmaceutical

The FDA last week approved Teva Pharmaceuticals (NYSE:TEVA) Cassipa sublingual film as a maintenance treatment for opioid dependence. There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams of buprenorphine and 4 milligrams of naloxone, bringing a new dosage […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Teva Pharmaceuticals

FDA approves first generic Epipen

August 17, 2018 By Sarah Faulkner

FDA

The FDA this week approved the first generic version of Mylan‘s (NSDQ:MYL) Epipen emergency allergy auto-injector. Teva Pharmaceuticals (NYSE:TEVA), which won the historic approval, plans to market the generic epinephrine auto-injector in 0.3mg and 0.15mg doses. There are other epinephrine auto-injectors on the market in the U.S., but Teva’s is the first that’s approved to directly […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Mylan, Teva Pharmaceuticals

FDA recalls heart failure, blood pressure drugs due to cancerous contaminant

July 16, 2018 By Sarah Faulkner

FDA

The FDA announced last week a voluntary recall of several high blood pressure and heart failure medications containing valsartan due to a cancerous impurity. Some valsartan drugs were found to contain N-nitrosodimethylamine (NDMA), a compound that is classified as a probable human carcinogen. Not all drugs containing valsartan were recalled, the FDA noted. Teva Pharmaceuticals (NYSE:TEVA), […]

Filed Under: Cardiovascular, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Recalls, Wall Street Beat Tagged With: majorpharmaceuticals, solcohealthcare, Teva Pharmaceuticals

With groundbreaking approval, Amgen launches new class of medicine for migraine patients

May 18, 2018 By Sarah Faulkner

Amgen

Amgen (NSDQ:AMGN) won FDA approval this week for its once-monthly Aimovig injection designed to prevent the onset of migraines in adults. The drug is the first of its kind – a molecule that blocks the receptor for a protein that is linked to migraine pain, the calcitronin gene-related peptide. Other major pharmaceutical companies like Eli Lilly (NYSE:LLY) […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Eli Lilly & Co., Teva Pharmaceuticals

Tribe looks to stop patent board’s review of Restasis IP

March 20, 2018 By Sarah Faulkner

gavel

Allergan (NYSE:AGN) and the St. Regis Mohawk Tribe asked the Federal Circuit last week to stop the U.S. Patent Trial and Appeal Board from reviewing the IP for Allergan’s blockbuster eye drug, Restasis. The move comes in response to the board’s February decision that sovereign immunity does not shield tribes from patent challenges. The board’s ruling […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Mylan, Teva Pharmaceuticals

Sen. McCaskill: Teva is “stonewalling” Senate investigation into opioid crisis

March 7, 2018 By Sarah Faulkner

capitol hill

Sen. Claire McCaskill (D-Mo.) said that Teva Pharmaceuticals (NYSE:TEVA) is “stonewalling” a Senate probe into the the role that opioid manufacturers have in the nation’s opioid crisis. In the senator’s initial inquiries with the generic drugmaker, McCaskill requested an array of documents detailing arrangements between Teva and its customers, as well as internal reviews of pharmacies […]

Filed Under: Featured, Legal News, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Teva Pharmaceuticals

Teva launches breath-activated asthma aerosol in U.S.

February 12, 2018 By Sarah Faulkner

Teva's Qvar RediHaler

Teva Pharmaceuticals (NYSE:TEVA) has launched its Qvar RediHaler inhalation aerosol in the U.S., marking the first time a breath-actuated inhaled corticosteroid is available for asthma patients as a prophylactic therapy. In contrast to traditional metered-dose inhalers, Teva’s Qvar RediHaler sends medication into the user’s lungs as they inhale. This feature eliminates the need for hand-breath coordination, […]

Filed Under: Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Teva Pharmaceuticals

Teva shares tumble after “challenging” Q4, FY17

February 8, 2018 By Sarah Faulkner

Teva Pharmaceutical

Shares in Teva Pharmaceuticals (NYSE:TEVA) fell today after the pharmaceutical company missed sales expectations on Wall Street with its fourth quarter results. The Israel-based company posted a net loss of -$11.6 billion, or -$11.43 per share, on sales of $5.46 billion for the 3 months ended Dec. 31, for a sales loss of -16% compared with […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Teva Pharmaceuticals

Teva inks deal to test drugs with ProBioGen’s artificial lymph node tech

February 7, 2018 By Sarah Faulkner

ProBiogen

Teva Pharmaceuticals (NYSE:TEVA) has inked a non-exclusive licensing deal to use ProBioGen‘s human artificial lymph node technology in the preclinical testing of the pharma company’s drug candidates. ProBioGen, a contract developer and manufacturer based in Berlin, designed its 3D micro-organoid model for companies to use to predict the reactions that their drugs will provoke in the […]

Filed Under: Featured, Pharmaceuticals, Preclinical Trials, Wall Street Beat Tagged With: probiogen, Teva Pharmaceuticals

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 7
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS